# Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

> **NCT04503694** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jules Bordet Institute** · enrollment: 72 (estimated)

## Conditions studied

- Rectal Cancer Stage II
- Rectal Cancer Stage III

## Interventions

- **DRUG:** Nivolumab 10 MG/ML Intravenous Solution
- **DRUG:** Regorafenib 30 MG Oral Tablet
- **RADIATION:** Radiotherapy
- **PROCEDURE:** Surgery
- **PROCEDURE:** Non-operative Management

## Key facts

- **NCT ID:** NCT04503694
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2032-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503694, "Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04503694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*